STOCK TITAN

Immix Biopharma, Inc. - IMMX STOCK NEWS

Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.

Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company leading the way in the development of innovative cell therapies for autoimmune diseases and hematologic malignancies. The company's flagship product, NXC-201, is a next-generation CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis and multiple myeloma. NXC-201 stands out due to its potential to be the world’s first 'Single-Day CRS' CAR-T, offering rapid treatment and the prospect of quick patient recovery.

Immix Biopharma leverages its proprietary TME Normalization Technology to develop Tissue-Specific Therapeutics (TSTx) that precisely target cancerous tissues while minimizing systemic side effects. Their leading projects include the NEXICART-1 and NEXICART-2 clinical trials, which are currently testing the efficacy and safety of NXC-201 in patients with relapsed/refractory conditions.

In recent developments, Immix Biopharma has received multiple Orphan Drug Designations (ODD) from both the FDA and the European Medicines Agency (EMA) for NXC-201 in treating AL Amyloidosis and multiple myeloma. This designation provides significant regulatory and financial incentives, highlighting the therapy's potential impact on these challenging diseases.

Immix Biopharma's IMX-110 is another key product in its pipeline, aimed at treating soft tissue sarcoma. Currently under evaluation in Phase 1b/2a trials, IMX-110 has already been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, underscoring its potential for treating rare cancers.

The company has made significant strides over the past year, including receiving FDA investigational new drug clearance for NXC-201, advancing ongoing clinical trials, and forming strategic partnerships with leading research institutions such as Memorial Sloan Kettering Cancer Center. Their commitment to pioneering cell therapies is further evidenced by their recent awareness campaign, Be Proactive in AL™, aimed at improving the diagnosis and treatment of AL Amyloidosis.

With a robust clinical dataset and strong regulatory support, Immix Biopharma is well-positioned to bring transformative therapies to market, addressing unmet medical needs in autoimmune diseases and cancer. For more information, please visit www.immixbio.com.

Rhea-AI Summary

Immix Biopharma (Nasdaq: IMMX) has expanded its clinical trial consortium by adding four additional oncology sites to enhance the testing of its drug IMX-110 for soft tissue sarcoma. The lead site in California has historically enrolled 2-3 patients monthly. As part of the trial, patients will receive CT scans every eight weeks to monitor tumor response, with data release commencing in Q1 2023. The FDA has granted orphan drug designation and rare pediatric disease designation for IMX-110, enabling potential fast track and priority review upon marketing approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary

Immix Biopharma (Nasdaq: IMMX) has successfully completed Good Manufacturing Practice (GMP) manufacturing of IMX-110, a drug candidate for clinical trials. This scaled-up process will support two upcoming clinical trials: one for monotherapy in soft tissue sarcoma and another combining IMX-110 with BeiGene's anti-PD-1 tislelizumab for advanced solid tumors. The FDA has granted orphan drug and rare pediatric disease designations for IMX-110, enabling it to benefit from expedited review processes. The company aims to initiate these trials in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
-
Rhea-AI Summary

Immix Biopharma (Nasdaq: IMMX) announced promising interim results for IMX-110 from a Soft Tissue Sarcoma (STS) mice study. After one treatment cycle, IMX-110 demonstrated a 75% survival rate compared to 0% for Trabectedin, an FDA-approved drug. This positions IMX-110 favorably in a potential $3 billion STS market projected to reach $6.5 billion by 2030. CEO Ilya Rachman expressed optimism ahead of two clinical trials for IMX-110 set to begin in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.06%
Tags
none
Rhea-AI Summary

Immix Biopharma (Nasdaq: IMMX) has authorized a $1 million stock buyback program to enhance shareholder value. The company, with approximately $18 million in cash and equivalents as of December 31, 2021, and 13.9 million shares outstanding, aims to execute purchases based on market conditions and regulatory considerations. CEO Ilya Rachman expressed confidence in reaching critical milestones with their lead asset, IMX-110, while emphasizing alignment with shareholder interests.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
buyback
-
Rhea-AI Summary

Immix Biopharma, Inc. (Nasdaq: IMMX) announced its Milestone Day Event on April 5, 2022, showcasing its drug development progress and the company’s financial position after raising $24.2 million in its IPO. Management outlined plans to begin two clinical trials in 2022, specifically for its lead asset, IMX-110, which targets oncology and immuno-dysregulated diseases. The event highlighted the company’s unique Tissue-Specific Therapeutics (TSTx) approach and its orphan drug designation for soft tissue sarcoma. For more information, visit immixbio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.01%
Tags
none
-
Rhea-AI Summary

Immix Biopharma, Inc. (Nasdaq: IMMX) announced plans for the IMMX Milestone Day Event on April 5, 2022, where management will discuss the company’s financial position, milestones, and market opportunities amid current volatility. The company raised $24.2 million from its December 2021 IPO and aims to initiate two clinical trials in 2022. CEO Ilya Rachman expressed confidence in achieving planned milestones with the capital raised, emphasizing the company's strategy to leverage market conditions for growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.9%
Tags
none
Rhea-AI Summary

Immix Biopharma (Nasdaq: IMMX) has initiated Good Manufacturing Practice (GMP) manufacturing for IMX-120, a biologic targeting inflammatory bowel disease (IBD). The company plans to file an Investigational New Drug (IND) application for IMX-120 in 2023, marking an important milestone for future clinical trials. The IBD market is projected to grow from $18.4 billion in 2019 to $21.4 billion by 2024, underscoring the potential market opportunity for IMX-120. This development highlights ImmixBio's commitment to advancing treatment options in the biopharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.5%
Tags
none
-
Rhea-AI Summary

Immix Biopharma has hosted an Investors Day event on February 1, 2022, where management responded to top-voted questions from verified shareholders. The session highlighted the company’s commitment to transparency and ongoing communication with investors. ImmixBio is focused on its lead asset, IMX-110, currently in Phase 1b/2a clinical trials for soft tissue sarcoma and rhabdomyosarcoma, supported by orphan drug and rare pediatric designations by the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.55%
Tags
none
-
Rhea-AI Summary

Immix Biopharma, Inc. (Nasdaq: IMMX) announced the initiation of Good Manufacturing Practice (GMP) scale-up for IMX-110, marking a significant step toward accelerating two clinical trials planned for 2022. The first trial focuses on IMX-110 monotherapy for soft tissue sarcoma, while the second tests the combination of IMX-110 with BeiGene's anti-PD-1 tislelizumab for advanced solid tumors. IMX-110 has received orphan drug and rare pediatric disease designations from the FDA, enabling fast-track review for its marketing approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.37%
Tags
Rhea-AI Summary

Immix Biopharma, Inc. (Nasdaq: IMMX) reports promising data on IMX-110 in combination with anti-PD-1, achieving a 63-day median survival in a KPC pancreatic cancer mouse model, compared to the historical median of 42 days from a standard 4-drug regimen. This significant result underlines the potential of IMX-110, which is set to enter a Phase 1b/2a clinical trial with BeiGene's tislelizumab in advanced solid tumors in 2022. The FDA has granted orphan drug and rare pediatric disease designations for IMX-110, positioning it well for future clinical advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags

FAQ

What is the current stock price of Immix Biopharma (IMMX)?

The current stock price of Immix Biopharma (IMMX) is $1.6 as of November 6, 2024.

What is the market cap of Immix Biopharma (IMMX)?

The market cap of Immix Biopharma (IMMX) is approximately 43.9M.

What is Immix Biopharma, Inc.?

Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing novel cell therapies for autoimmune diseases and hematologic malignancies.

What are the main products of Immix Biopharma?

The main products include NXC-201, a next-generation CAR-T cell therapy for AL Amyloidosis and multiple myeloma, and IMX-110, a treatment for soft tissue sarcoma.

What is NXC-201?

NXC-201 is a CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis and multiple myeloma, potentially offering the first 'Single-Day CRS' treatment.

What is the significance of the Orphan Drug Designation?

Orphan Drug Designation provides regulatory and financial incentives for developing treatments for rare diseases, highlighting the potential impact of therapies like NXC-201.

What recent achievements has Immix Biopharma made?

Recent achievements include FDA investigational new drug clearance for NXC-201, multiple ODD awards, and advancements in clinical trials and strategic partnerships.

What is the Be Proactive in AL™ campaign?

The Be Proactive in AL™ campaign aims to increase awareness and early diagnosis of AL Amyloidosis, and educate patients about available treatment options.

What is IMX-110?

IMX-110 is a tissue-specific therapeutic being evaluated in Phase 1b/2a trials for treating relapsed/refractory soft tissue sarcoma, with FDA Orphan Drug and Rare Pediatric Disease Designations.

Where can I find more information about Immix Biopharma?

You can find more information on their official website at www.immixbio.com.

What are the key features of NXC-201?

Key features of NXC-201 include its potential for 'Single-Day CRS' treatment, rapid patient recovery, and effectiveness in treating AL Amyloidosis and multiple myeloma.

Who are the key partners of Immix Biopharma?

Key partners include leading research institutions like Memorial Sloan Kettering Cancer Center, contributing to the advancement of clinical trials and research.

Immix Biopharma, Inc.

Nasdaq:IMMX

IMMX Rankings

IMMX Stock Data

43.92M
27.45M
40.18%
17.63%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ANGELES